Health-care companies rose after strong earnings from one obesity-drug maker.
Eli Lilly shares rose after it reiterated its forecast for 32% 2025 revenue growth, amid rising demand for its Zepbound and Mounjaro obesity drugs.
On Wednesday, Novo Nordisk calmed fears of slowing demand growth for the GLP-1 class of drugs, projecting a robust 20% increase in companywide sales at the midpoint of its 2025 projection.
Shares of Bristol-Myers Squibb fell after the cancer-drug maker's outlook lagged some Wall Street firms' targets.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
February 06, 2025 17:21 ET (22:21 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.